Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 1
2007 2
2008 1
2009 5
2011 1
2012 7
2013 8
2014 7
2015 4
2016 4
2017 6
2018 4
2019 7
2020 4
2021 3
2022 9
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
LDLR is used as a cell entry receptor by multiple alphaviruses.
Zhai X, Li X, Veit M, Wang N, Wang Y, Merits A, Jiang Z, Qin Y, Zhang X, Qi K, Jiao H, He WT, Chen Y, Mao Y, Su S. Zhai X, et al. Nat Commun. 2024 Jan 20;15(1):622. doi: 10.1038/s41467-024-44872-5. Nat Commun. 2024. PMID: 38245515 Free PMC article.
[Optimization of extraction process for classic prescription Yihuang Decoction based on Box-Behnken design-response surface methodology, standard relation, and analytic hierarchy process combined with entropy weight method].
Lu XY, Bi JY, Li MH, Mamujiang R, Zhai XF, Gu Y, Song Y, Peng ZW, Li HH, DU SY, Bai J. Lu XY, et al. Zhongguo Zhong Yao Za Zhi. 2023 Nov;48(21):5798-5808. doi: 10.19540/j.cnki.cjcmm.20230822.301. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 38114175 Chinese.
Transmission of HCoV-OC43 to pet hamsters.
He H, Li X, Wang Y, Zhang C, Yu H, Li D, Li X, Jiang Z, Sun J, Zhai X. He H, et al. Among authors: zhai x. Microb Pathog. 2023 Dec;185:106364. doi: 10.1016/j.micpath.2023.106364. Epub 2023 Oct 1. Microb Pathog. 2023. PMID: 37788727
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
79 results